Navigation Links
Boston Scientific Announces Results for First Quarter Ended March 31, 2011
Date:4/20/2011

NATICK, Mass., April 20, 2011 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced financial results for the first quarter ended March 31, 2011, as well as net sales and earnings per share (EPS) guidance for the second quarter and updated guidance for the full year 2011. The Company exceeded its adjusted EPS guidance range for the quarter and raised adjusted EPS guidance for the full year 2011. First quarter GAAP results included a previously anticipated gain recognized on the sale of the Neurovascular business of $759 million pre-tax ($530 million after-tax), net of separation costs. In addition, primarily due to a reduction in the estimated size of the U.S. Cardiac Rhythm Management (CRM) market, which led to lower projected U.S. CRM results compared to prior forecasts, the Company also recorded a $723 million (pre- and after-tax) estimated goodwill impairment charge associated with its U.S. CRM business unit during the quarter. As a result, GAAP EPS for the first quarter of 2011 was below previous guidance, and the Company's updated full year GAAP EPS guidance reflects this charge. The amount of the goodwill impairment charge is subject to finalization and is estimated to range between $650 million and $800 million.

First quarter highlights:

  • Achieved sales of $1.925 billion, at the high end of the Company's previous guidance range, and adjusted EPS of $0.22, exceeding previous guidance; reported GAAP earnings of $0.01 per share, lower than previous guidance due primarily to the impact of a $0.47 per share goodwill impairment charge.
  • Maintained leadership position in the drug-eluting stent market with a worldwide share of 36 percent and U.S. share of 46 percent (each excluding a negative one-share point impact of product transition reserves), and continued to grow PROMUS Element™ sales, with a European market share of more
    '/>"/>

  • SOURCE Boston Scientific Corporation
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

    Related medicine technology :

    1. Dainippon Sumitomo Pharma Co., Ltd. and Boston Biomedical, Inc. Enter Strategic Partnership on Anti-Cancer Drugs Targeting Cancer Stem Cells
    2. Boston Scientific Begins International Clinical Trial Enrollment for INNOVA™ Self-Expanding Bare-Metal Stent System
    3. Boston Scientific ION™ Platinum Chromium Stent System Demonstrates Strong Performance in Analysis of PERSEUS and TAXUS ATLAS Clinical Trial Data
    4. Hologic, Hospira, Boston Scientific, Allergan to Participate in Leading Medical Device Manufacturing Symposium
    5. Boston Scientific Announces Its ACC 2011 Schedule
    6. Boston Scientific Receives FDA Approval of New Clik(TM) Anchor for Precision Plus(TM) Spinal Cord Stimulator System
    7. Boston Scientific to Webcast Analyst Event
    8. Boston Scientific to Present at Barclays Capital 2011 Global Healthcare Conference
    9. Boston Scientific Announces European Approval and Launch of OMEGA™ Platinum Chromium Stent System
    10. Unilife to Present at the 31st Annual Cowen Health Care Conference on Wednesday, March 9, 2011 in Boston
    11. Boston Scientific Strengthens Structural Heart Product Portfolio By Completing Acquisition of Atritech
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/28/2014)... 28, 2014 CTI BioPharma Corp. (CTI) (NASDAQ ... its second quarter 2014 financial results on Monday, August ... markets. Following the announcement, members of the management team ... results and provide a general corporate update at 4:30 ... can be obtained as follows: Monday, August ...
    (Date:7/25/2014)... 25, 2014  Corporate libraries are constantly being faced ... in technology and how to cope with flat or ... pharmaceutical and medical device industries are increasingly finding it ... services they provide. According to recent ... many forces of change that leading corporate libraries are ...
    (Date:7/25/2014)...  Depomed, Inc. (NASDAQ: DEPO ) today ... 2014 financial results after the market closes on Wednesday, August ... beginning at 4:30 pm EDT, 1:30 pm PDT to discuss its ... dialing 877-317-6789 ( United States ) or ... via a live webcast on the investor relations section ...
    Breaking Medicine Technology:CTI BioPharma to Report Second Quarter 2014 Financial Results on August 4, 2014 2Forces of Change Reshaping Corporate Libraries & Information Services 2Depomed To Report Second Quarter Fiscal Year 2014 Financial Results On Wednesday, August 6, 2014 2
    ... N.C., March 4, 2011 The pressure for a ... greater with organizations across the pharmaceutical sector facing pipeline ... Facing an ever-changing launch landscape, product launch leaders ... new therapies through the labyrinth of regulatory and marketplace ...
    ... 2011 Cardica, Inc. (Nasdaq: CRDC ) ... stapling device developed by Cardica has received CE Mark ... marking process, Cardica has obtained a Full Quality Assurance ... this certification, after successful completion of development, Cardica can ...
    Cached Medicine Technology:Pharmaceutical Launch Excellence Services Delivers Market Entry Road Map 2Cardica Receives European CE Mark for Initial Microcutter™ Surgical Cutting and Stapling Device 2Cardica Receives European CE Mark for Initial Microcutter™ Surgical Cutting and Stapling Device 3Cardica Receives European CE Mark for Initial Microcutter™ Surgical Cutting and Stapling Device 4
    (Date:7/28/2014)... With California in a record draught ... that a fire blanket that is over ... development by SunSeeker Enterprises, Inc. The fire blanket—utilizing the ... the extreme heat of re-entry into the Earth's atmosphere—will ... , “Our firefighters routinely lay their very lives on ...
    (Date:7/28/2014)... July 28, 2014 At some point in ... where they’re forced to contact the authorities. Distinguishing the ... than it initially seems. , Not every dangerous situation is ... stolen, a person get mugged, or a bank get held ... leading onlookers to be more passive than they otherwise should. ...
    (Date:7/28/2014)... (PRWEB) July 28, 2014 Drorit Silverman, ... unveiled new plans to raise investment capital through her ... fitness concept in the United States. , According to ... of 24/7 fitness centers provide a great window of ... rapidly expanding space. In addition to this, Silverman looks ...
    (Date:7/28/2014)... July 28, 2014 The report ... Applications (Food & Beverages, Cleaning Agents, Bio-Fuel, Animal ... to 2018” defines and segments the global industrial ... global value for industrial enzymes. It also identifies ... enzymes market with analysis of trends, opportunities, burning ...
    (Date:7/28/2014)... School of Medicine (BUSM) report variants in a new ... Alzheimer,s disease (AD). The discovery of this novel genetic ... target PLXNA4 specifically. These findings appear in the ... frequent age-related dementia affecting 5.4 million Americans including 13 ... than 40 percent of people age 85 and older. ...
    Breaking Medicine News(10 mins):Health News:Revolutionary Fire Blanket Offers Over 200 Percent More Fire Protection to Firefighters and Homes 2Health News:Take Action To Protect Your Fellow Citizens 2Health News:Take Action To Protect Your Fellow Citizens 3Health News:Pro Bodybuilder Drorit Silverman Confirms Plans to Raise Money for Investment in the Popular 24/7 Fitness Concept 2Health News:Industrial Enzymes Market Worth $5,987.5 Million by 2018 - Report by MarketsandMarkets 2Health News:Industrial Enzymes Market Worth $5,987.5 Million by 2018 - Report by MarketsandMarkets 3Health News:Industrial Enzymes Market Worth $5,987.5 Million by 2018 - Report by MarketsandMarkets 4Health News:Researchers identify potential biomarker for AD 2
    ... A recent study estimates that nearly 30,000 men will ... study offers hope for these patients: // The combination ... improves survival rates. ,AST inhibits the release of ... three years of AST with radiation therapy has been ...
    ... compression stockings can reduce complications after a blood clot ... uncomfortable .// ,Some of the common complications with ... leg include swelling, skin discoloration, numbness, chronic pain, hardening ... suggested that elastic stockings could help patients with blood ...
    ... of people worldwide . It is the most common form ... are still unknown and there is no cure. ,New ... to treating Alzheimer’s disease. A team of researchers tested ... were given sage oil capsules, and some were given placebos. ...
    ... to researchers a group of cells, called satellite cells, ... older people maintain // their youthfulness. These cells rescue ... They also generate new cells for future repairs. Previous ... protein called Notch is activated by another protein called ...
    ... Chronic obstructive pulmonary disease, an often neglected disease of the ... The vast majority of people with the disease are smokers. ... from wood fires also comes into play in some cases. ... in fact, it will be the third leading cause of ...
    ... news for the many adults and children who have endured ... ,Developing a vaccine to prevent group A streptococcal infections has ... years. Group A streptococcus is responsible for a variety of ... most common. ,The vaccine trial included 28 adults ...
    Cached Medicine News:
    The Advance Unicompartmental Knee System is designed with bone conserving femoral and tibial components that provide reproducible results within a minimal incision. Uni metal backed tibial component....
    ...
    ...
    ... Severe revision options for the knee and ... modular system for the knee and hip ... that include surgical indication, implant selection, connection ... individual needs. This system addresses the needs ...
    Medicine Products: